Pulling Back the Curtain: Robert A. Kyle, MD – ASH Clinical News
Pulling Back the Curtain: Robert A. Kyle, MD – Multimedia, Sound Bites – ASH Clinical News
Related Articles
When to Stay or Leave Your Physician Job – FREE Webinar
At the free, LIVE class, you’ll get everything you need to make your decision & upgrade your job in 2025, regardless if you stay or…
Trust in American health care: What’s driving the decline?
Trust in U.S. health care is declining due to systemic issues, including economic strains, fraud, and leadership failures, but approaches like value-based care, patient engagement,…
No, CXR for Pediatric Pneumonia Does NOT have a 98% Negative Predictive Value
A blog about biases in the conduct, interpretation, and application of evidence from clinical trials in medicine
[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial
Our results suggest that [89Zr]Zr-girentuximab PET–CT has a favourable safety profile and is a highly accurate, non-invasive imaging modality for the detection and characterisation of…
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma | NEJM
Muscle-invasive urothelial carcinoma is an aggressive disease with high rates of relapse. Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive…
Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma☆
Belzutifan is a first-in-class hypoxia-inducible factor subunit 2α (HIF-2α) inhibitor approved at a dose of 120 mg once daily for certain adults with VHL disease…
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma | NEJM
Belzutifan, a hypoxia-inducible factor 2α inhibitor, showed clinical activity in clear-cell renal-cell carcinoma in early-phase studies. In a phase 3, multicenter, open-label, active-controlled tri…
Medicare’s $2,000 prescription drug cap expected to bring major relief to cancer patients
The new price cap, part of the Inflation Reduction Act, will apply to all prescription drugs covered by Medicare.
Reach 2024: Racing for Cause – CIFAR
From AI to optogenetics, new techniques and strategies are enabling researchers to learn from cognitive disorders and probe the root of consciousness